Biopharmaceuticals

Hamilton, Ontario – September 09, 2026 -- AtomVie Global Radiopharma has opened a new 72,300-square-foot production facility at 10 Aeropark Boulevard in Hamilton, Ontario, backed by more than $160 million in investment and marking the largest single-site radiopharmaceutical CDMO facility in North America.

New facility multiplies AtomVie's manufacturing output tenfold

The purpose-built plant increases AtomVie's production capacity by a factor of ten, supporting both low- and high-throughput manufacturing. The site is designed to handle the full lifecycle of radiopharmaceutical production, from early-stage clinical development through commercial-scale manufacturing, with flexible space reserved for future client requirements.

Cambridge, Massachusetts – September 09, 2026 -- Insilico Medicine has published data in Nature Biotechnology showing that its AI-designed idiopathic pulmonary fibrosis (IPF) candidate rentosertib reversed predicted biological age by up to six years in some patients, based on six independently developed proteomic aging clocks.

Yantai – September 09, 2026 -- CelluPro has secured EXCiPACTTM GMP certification for pharmaceutical auxiliary materials, becoming the first China-based cell culture media supplier to achieve the credential.

CelluPro adds EXCiPACT GMP to existing ISO certification portfolio

The biotechnology firm, which specializes in serum-free cell culture media and bioprocessing solutions, now holds EXCiPACTTM certification alongside ISO 9001, ISO 13485, ISO 14001, ISO 45001 and ISO 22301 certifications covering quality management, environmental management, occupational health and safety, and business continuity.

Melbourne – – September 09, 2026 -- Nutromics, a Melbourne-based wearable diagnostics startup, has appointed Professor Kevin W. Plaxco, the inventor of its core DNA-based sensing technology, as Chief Scientific Officer ahead of its first product launch planned for 2027.

Plaxco takes over as CSO from Justin Gooding, who remains on the Biosensor Advisory Board

Professor Plaxco succeeds Scientia Professor Justin Gooding in the role. Gooding will continue to serve on Nutromics' Biosensor Advisory Board, a group Plaxco previously chaired as an advisor since the company licensed his technology from co-founders Peter Vranes and Hitesh Mehta.

Seongnam, South Korea – September 09, 2026 -- Rznomics Inc. (KOSDAQ: 476830) has achieved up to a seven-fold increase in circular RNA (circRNA) production efficiency through engineering upgrades to its proprietary Self-Targeting and Splicing (STS) platform, according to peer-reviewed research published in Nucleic Acids Research on September 4, 2026.

Optimized STS method doubles circularization efficiency versus industry-standard PIE technique

In tests using Factor VIII RNA measuring approximately 7.8 kilo-nucleotides in length, the upgraded STS approach delivered roughly twice the circularization efficiency of the widely used Permuted Intron–Exon (PIE) method, a standard benchmark in circRNA manufacturing. The finding directly addresses a persistent industry constraint: circularization efficiency typically drops as RNA length increases, limiting the size of genes that can be produced at commercial scale.

Auckland – September 09, 2026 -- Aroa Biosurgery Limited (ASX: ARX) reported that interim results from its MASTRR Registry found deep tissue infection in just 0.7% of patients treated with its Myriad Matrix and Myriad Morcells bioscaffolds, with no adverse events causally linked to the products.

Largest published prospective bioscaffold study covers 411 patients, 474 defects

The peer-reviewed analysis, published in Advances in Therapy, tracked 411 patients and 474 soft tissue defects across 10 US centers. Aroa says this represents, to its knowledge, the largest published prospective analysis of a bioscaffold in in-patient soft tissue reconstruction.

Shanghai – September 09, 2026 -- Harbour BioMed (HKEX: 02142.HK) shares became eligible for trading under the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs, opening direct access for qualified mainland Chinese investors effective immediately.

Market capitalization crosses HK$10 billion threshold

The inclusion follows the Company's market capitalization steadily surpassing HK$10 billion, placing it among large- and mid-cap biopharmaceutical issuers on the Hong Kong exchange.

First-half 2026 revenue rises 20.9% to $122.5 million

Harbour BioMed recorded total revenue of approximately US$122.5 million in the first half of 2026, up 20.9% year-over-year. Adjusted net profit reached approximately US$71.6 million, marking seven consecutive profitable half-years. Cash and cash equivalents stood at approximately US$359.2 million as of June 30, 2026.

Shanghai – September 09, 2026 -- Clover Biopharmaceuticals (HKEX: 02197) reported positive preliminary Phase 2 data in Australia for two combination respiratory vaccine candidates, SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), targeting older adults aged 60-85.

Trial enrolled 420 older adults across multiple Australian sites

The randomized, observer-blinded study randomized 420 participants to receive SCB-1022, SCB-1033 or placebo. Antibody titers at 28 days post-vaccination were in line with or trended higher than prior Phase 1 results.

Yantai – September 09, 2026 -- CelluPro has become the first Chinese cell culture media supplier to receive EXCiPACTTM GMP Certification for Pharmaceutical Auxiliary Materials, adding an internationally recognized quality benchmark to its biomanufacturing supply chain.

EXCiPACT Certification Validates Manufacturing Controls and Traceability

The EXCiPACTTM scheme sets GMP requirements for materials used in biopharmaceutical manufacturing, assessing quality management, manufacturing controls, traceability, and supply chain practices. CelluPro's certification adds to an existing compliance portfolio that includes ISO 9001, ISO 13485, ISO 14001, ISO 45001, and ISO 22301, covering quality management, environmental management, occupational health and safety, and business continuity.

Nottingham – September 09, 2026 -- Isomab Ltd has published a systematic review showing no increased cancer or retinopathy risk from pro-angiogenic therapies for coronary artery disease, removing a two-decade safety barrier that has constrained development across the field.

Review of 636 patients finds malignancy rates below population norms

The analysis covered 11 clinical studies conducted between 2002 and 2024, spanning 636 patients with angina or peripheral artery disease -- 441 receiving pro-angiogenic therapy and 195 on placebo -- with follow-up periods ranging from two to 12 years. Mean malignancy incidence was 0.84 per 100 patient-years for the treatment group versus 0.72 for placebo, both figures falling below the age-matched population rate of 1.0 per 100 patient-years. Retinal events were rare in both cohorts and also below population benchmarks.